International Journal of Nephrology and Renovascular Disease (Oct 2020)
Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives
Abstract
Elton Jonh Freitas Santos,1 Raimunda Sheyla Carneiro Dias,1 Janielle Ferreira de Brito Lima,1 Natalino Salgado Filho,2 Alcione Miranda dos Santos2 1University Hospital of the Federal University of Maranhão, São Luís, Brazil; 2Federal University of Maranhão, São Luís, BrazilCorrespondence: Elton Jonh Freitas SantosUniversity Hospital of the Federal University of Maranhão, Rua Barão de Itapary – 227, Centro, São Luís CEP 65020-070, MA, BrazilTel +98 2109.1089/2109.1024Email [email protected]: Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin deficiency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as it can increase the risk of death in patients with kidney disease. Therefore, we provide a discussion of the current literature regarding the factors that can modify the response to this class of drugs and the strategies that can be considered to optimize the benefits of treating anemia.Keywords: anemia, chronic kidney disease, erythropoietin, drug resistance
